Literature DB >> 16779710

Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver.

Chihiro Tamaki1, Sumio Ohtsuki, Takeshi Iwatsubo, Tadafumi Hashimoto, Kaoru Yamada, Chiori Yabuki, Tetsuya Terasaki.   

Abstract

PURPOSE: To identify the molecules responsible for amyloid beta-peptide (1-40) (Abeta(1-40)) uptake by the liver, which play a major role in the systemic clearance of Abeta(1-40).
METHODS: The liver uptake index method was used to examine the mechanisms of Abeta(1-40) uptake by the liver in vivo.
RESULTS: [125I]Abeta(1-40) uptake by the rat liver was concentration-dependent (50% saturation concentration = 302 nM). The inhibitory spectrum of Abeta fragments indicated that 17-24 in Abeta (LVFFAEDV) was the putative sequence responsible for hepatic Abeta(1-40) uptake. Receptor-associated protein (RAP) inhibited [125I]Abeta(1-40) uptake by 48%. RAP-deficient mice, in which low-density lipoprotein receptor-related protein 1 (LRP-1) expression was suppressed, showed a 46% reduction in [125I]Abeta(1-40) uptake by the liver. siRNA-mediated suppression of LRP-1 expression in the liver resulted in a reduction in [125I]Abeta(1-40) uptake by 64%. Both the expression of LRP-1 in the liver and the hepatic Abeta(1-40) uptake were significantly reduced in 13-month-old rats compared with 7-week-old rats.
CONCLUSIONS: LRP-1 is the major receptor responsible for the saturable uptake of plasma free Abeta(1-40) by the liver. Reduction of LRP-1 expression will play a role in the age-related reduction in hepatic Abeta(1-40) clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779710     DOI: 10.1007/s11095-006-0208-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  44 in total

1.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation.

Authors:  J Herz; D E Clouthier; R E Hammer
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

2.  Systemic catabolism of Alzheimer's Abeta40 and Abeta42.

Authors:  Jorge Ghiso; Marcos Shayo; Miguel Calero; Douglas Ng; Yasushi Tomidokoro; Samuel Gandy; Agueda Rostagno; Blas Frangione
Journal:  J Biol Chem       Date:  2004-08-20       Impact factor: 5.157

Review 3.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

4.  Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide.

Authors:  T Pillot; M Goethals; B Vanloo; C Talussot; R Brasseur; J Vandekerckhove; M Rosseneu; L Lins
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

5.  Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.

Authors:  M Citron; T S Diehl; G Gordon; A L Biere; P Seubert; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy.

Authors:  J B Mackic; M H Weiss; W Miao; E Kirkman; J Ghiso; M Calero; J Bading; B Frangione; B V Zlokovic
Journal:  J Neurochem       Date:  1998-01       Impact factor: 5.372

7.  The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease.

Authors:  E M Castaño; F Prelli; C Soto; R Beavis; E Matsubara; M Shoji; B Frangione
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

8.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans.

Authors:  Christopher C T Smith; D John Betteridge
Journal:  Neurosci Lett       Date:  2004-08-26       Impact factor: 3.046

10.  Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.

Authors:  Jasmina B Mackic; James Bading; Jorge Ghiso; Larry Walker; Thomas Wisniewski; Blas Frangione; Berislav V Zlokovic
Journal:  Vascul Pharmacol       Date:  2002-06       Impact factor: 5.773

View more
  43 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 3.  The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

Authors:  R Deane; A Sagare; B V Zlokovic
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 4.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

5.  Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease.

Authors:  Kole D Meeker; James S Meabon; David G Cook
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats.

Authors:  Loqman A Mohamed; Hisham Qosa; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2015-03-30       Impact factor: 4.418

Review 7.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.

Authors:  Abhay P Sagare; Robert D Bell; Berislav V Zlokovic
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

8.  A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain.

Authors:  Abhay P Sagare; Robert D Bell; Alaka Srivastava; Jesse D Sengillo; Itender Singh; Yoichiro Nishida; Nienwen Chow; Berislav V Zlokovic
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

Review 9.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

Review 10.  New therapeutic targets in the neurovascular pathway in Alzheimer's disease.

Authors:  Berislav V Zlokovic
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.